First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with other solid tumors: Safety and efficacy results from a phase I study.

被引：0
|
作者：
Bai, Xueli
Xu, Qin
Liang, Xinjun
Chu, Qian
Zhang, Xiaochen
Chen, Yiwen
Xu, Nong
Fang, Weijia
Shan, Jianzhen
Jiang, Weiqin
Zhou, Jianya
Zheng, Yu-Long
Long, Sixiang
Chen, Haonan
Zhao, Li
Wang, Hongli
Sun, Jiya
Sun, Xing
Zhou, Hui
Liang, Tingbo
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[2] Fujian Prov Canc Hosp, Dept Gynecol Oncol, Fuzhou, Peoples R China
[3] Hubei Canc Hosp, Dept Abdominal Oncol, Wuhan, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China
[5] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatopancreatobiliary Surg, Hangzhou, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China
[7] Innovent Biol Suzhou Co Ltd, Suzhou, Peoples R China
[8] Innovent Biol Suzhou Co Ltd, Beijing, Peoples R China
[9] Innovent Biol Suzhou Co Ltd, Shanghai, Peoples R China
[10] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14593
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study.
    Chen, Yiwen
    Liang, Xinjun
    Chen, Yu
    Wang, Hui
    Sun, Yuping
    Pan, Yueyin
    Zhang, Jian
    Cui, Jiuwei
    Chu, Qian
    Dai, Guang-Hai
    Kang, Liang
    Ma, Huiwen
    Shan, Jianzhen
    Fang, Weijia
    Zheng, Yu-Long
    Xu, Nong
    Jiang, Weiqin
    Wei, Cong
    Zhao, Li
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study
    Chen, Yu
    Lin, Jing
    Wang, Hui
    Zhang, Weizhen
    Liang, Xinjun
    Cui, Jiuwei
    Sun, Yuping
    Fang, Meiyu
    Pan, Yueyin
    Chu, Qian
    Bai, Xueli
    Zhang, Jian
    Li, Ning
    Zhang, Xiaoshi
    Zhao, Li
    Chen, Haonan
    Wang, Hongli
    Chen, Yuling
    Sun, Xing
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
    Bai, X.
    Chen, Y.
    Chen, Y.
    Liang, X.
    Wang, H.
    Sun, Y.
    Chu, Q.
    Pan, Y.
    Cui, J.
    Fang, J.
    Zhang, W.
    Xu, Q.
    Zhang, J.
    Liu, X.
    Dai, G.
    Kang, L.
    Li, N.
    Fang, M.
    Zhou, H.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 (07) : 681 - 682
  • [4] First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase I Study
    Zhou, J.
    Xu, N.
    Shan, J.
    Wang, Y.
    Fang, W.
    Wang, H.
    Pan, Y.
    Chen, Y.
    Liang, X.
    Chu, Q.
    Cui, J.
    Sun, Y.
    Fang, J.
    Liu, X.
    Li, N.
    Long, S.
    Chen, Y.
    Zhao, L.
    Wang, H.
    Liang, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S97 - S97
  • [5] First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363+bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study
    Lin, Z. Y.
    Ma, H.
    Liang, X.
    Zhao, L.
    Yu, D.
    Xue, J.
    Yang, S.
    Hu, J.
    Liu, J.
    Zhang, D.
    Yin, Z.
    Yuan, M.
    Zhao, L.
    Wang, H.
    Wei, C.
    Ding, L.
    Chen, Y.
    Zhou, H.
    Zhang, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S466 - S466
  • [6] The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
    Ruan, Dan-Yun
    Wei, Xiao-Li
    Liu, Fu-Rong
    Hu, Xi-Chun
    Zhang, Jian
    Ji, Dong-Mei
    Huang, Ding-Zhi
    Zhao, Yan-Qiu
    Pan, Hong-Min
    Liao, Wang-Jun
    Yang, Kun-Yu
    Xu, Nong
    Lu, Xiao-Xiao
    Chen, Yu-Ling
    Zhang, Wen
    Zhou, Hui
    Zhao, Hong-Yun
    Xu, Rui-Hua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [7] Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
    Coward, Jermaine
    Mislang, Anna Rachelle Austria
    Frentzas, Sophia
    Lemech, Charlotte Rose
    Nagrial, Adnan
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors
    Qin, Shukui
    Cheng, Ying
    Wang, Qiming
    Cheng, Shuxia
    Chai, Xiaoli
    Wu, Lihua
    Yu, Yan
    Shi, Jianhua
    Li, Xiumin
    Fan, Lianlian
    Xia, Jin
    Huang, Yisheng
    Ji, Yinghua
    Zhuang, Zhixiang
    Yang, Lei
    Jiang, Ou
    Zheng, Qinhong
    Liao, Sihai
    Yi, Shanyong
    Ye, Huangyang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial
    Du, Yiqun
    Zhang, Jian
    Sun, Meili
    Wen, Qing
    Zheng, Yawen
    Tolcher, Anthony W.
    Sommerhalder, David
    Wang, Zhen
    Li, Xiumin
    Gao, Zhenyuan
    Zhou, Huan
    Liu, Lian
    Wang, Benjie
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Li, Chao
    Li, Jiangfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results
    Rixe, Olivier
    Tang, Shou-Ching
    Sahebjam, Solmaz
    Mita, Monica M.
    Mita, Alain C.
    Rosen, Lee S.
    Bisht, Arnima
    Fandi, Abderrahim
    Rohlff, Christian
    Mehta, Rutika
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345